XML 59 R46.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Collaborative and Other Relationships (Details) $ in Thousands |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 25, 2022 USD ($) dose | Sep. 15, 2021 USD ($) | Nov. 05, 2019 USD ($) | Sep. 06, 2018 USD ($) dose | Sep. 30, 2013 USD ($) | Aug. 31, 2020 USD ($) | Jun. 30, 2000 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) dose | Sep. 30, 2021 USD ($) | Mar. 31, 2015 USD ($)
Collaborative and Other Relationships [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  |  |  |  | $ 75,827 | $ 40,994 | $ 191,282 | $ 110,012 |
U.S. Department of Health and Human Services |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement contract value |  |  |  | $ 34,660 |  |  |  |  |  |  |  |
Contract term (in years) |  |  |  | 5 years |  |  |  |  |  |  |  |
U.S. Department of Health and Human Services | RAPIVAB |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Maximum number of products, doses | dose |  |  |  | 50,000 |  |  |  |  |  | 50,000 |  |
Number of doses delivered, doses | dose | 10,000 |  |  |  |  |  |  |  |  | 39,980 |  |
Proceeds from collaborators | $ 6,932 |  |  |  |  |  |  |  |  | $ 27,714 |  |
Torii Pharmaceutical Co. [Member] |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  | $ 22,000 |  |  |  |  |  |  |  |  |
Potential milestone payments receivable if regulatory approval before specified date |  |  | $ 15,000 |  |  |  |  |  |  |  |  |
Maximum customary reduction on royalty rate |  |  | 50.00% |  |  |  |  |  |  |  |  |
Royalty payments receivable, expiration term from first commercial (in years) |  |  | 10 years |  |  |  |  |  |  |  |  |
Torii Pharmaceutical Co. [Member] | Minimum |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate if maintains sakigake designation |  |  | 20.00% |  |  |  |  |  |  |  |  |
Torii Pharmaceutical Co. [Member] | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate if maintains sakigake designation |  |  | 40.00% |  |  |  |  |  |  |  |  |
Base Contract |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Government contract receivable |  |  |  |  |  |  |  |  |  |  |  | $ 16,265
Additional Development Options |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Government contract receivable |  |  |  |  |  |  |  |  |  |  |  | 22,855
ASPRBARDA Contract |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Government contract receivable |  |  |  |  |  |  |  |  |  |  |  | $ 39,120
Proceeds from awards for research and development contracts |  |  |  |  |  |  |  |  |  | $ 20,574 |  |
AECOM and IRL |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment minimum |  |  |  |  |  |  | $ 1,400 |  |  |  |  |
Milestone payment maximum |  |  |  |  |  |  | 4,000 |  |  |  |  |
Annual license fee minimum |  |  |  |  |  |  | 150 |  |  |  |  |
Annual license fee maximum |  |  |  |  |  |  | $ 500 |  |  |  |  |
National Institute of Allergy and Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Expected receivable from awards for research and development contracts |  | $ 47,315 |  |  | $ 45,931 |  |  |  |  |  |  |
Potential aggregate maximum amount of funding |  |  |  |  |  | $ 43,908 |  |  |  |  |  |
Collaborative agreement contract value |  |  |  |  |  | $ 6,326 |  |  |  |  |  |
UAB |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Period of agreement (in years) |  |  |  |  |  |  |  |  |  | 25 years |  |
Renewable period of agreement (in years) |  |  |  |  |  |  |  |  |  | 5 years |  |

X
- Definition Represents annual maximum license fee. + References No definition available. + Details
Name: | bcrx_AnnualLicenseFeeMaximum
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represent minimum annual license fee. + References No definition available. + Details
Name: | bcrx_AnnualLicenseFeeMinimum
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of product. + References No definition available. + Details
Name: | bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents collaborative agreement contract value. + References No definition available. + Details
Name: | bcrx_CollaborativeAgreementContractValue
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Period of time between the contract date and its expiration. + References No definition available. + Details
Name: | bcrx_ContractTerm
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents expected receivable from awards for research and development contracts. + References No definition available. + Details
Name: | bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The maximum percentage of customary reductions allowed on royalty rate. + References No definition available. + Details
Name: | bcrx_MaximumCustomaryReductionOnRoyaltyRate
Namespace Prefix: | bcrx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Information on the maximum number of doses of RAPIVAB permitted under the contract. + References No definition available. + Details
Name: | bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents milestone payment maximum. + References No definition available. + Details
Name: | bcrx_MilestonePaymentMaximum
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents milestone payment minimum. + References No definition available. + Details
Name: | bcrx_MilestonePaymentMinimum
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number Of Products Obtained Doses + References No definition available. + Details
Name: | bcrx_NumberOfProductsObtainedDoses
Namespace Prefix: | bcrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents period of agreement. + References No definition available. + Details
Name: | bcrx_PeriodOfAgreement
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of potential milestone payments receivable if regulatory approval is granted. + References No definition available. + Details
Name: | bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeMilestone
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents proceeds from awards for research and development contracts. + References No definition available. + Details
Name: | bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts
Namespace Prefix: | bcrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents renewable period of agreement. + References No definition available. + Details
Name: | bcrx_RenewablePeriodOfAgreement
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The expiration term of the royalty payments from first commercial date. + References No definition available. + Details
Name: | bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial
Namespace Prefix: | bcrx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review. + References No definition available. + Details
Name: | bcrx_RoyaltyRateIfMaintainsSakigakeDesignation
Namespace Prefix: | bcrx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of receivables that are derived from government contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 310 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126938201&loc=d3e55295-109406 + Details
Name: | us-gaap_GovernmentContractReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bcrx_RAPIVABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |